May 21, 2018 – FCX-007 well-tolerated up to 52 weeks post-administration – – Continued positive trends noted in wound healing and pharmacology signals, including type VII collagen expression and evidence of anchoring fibrils – – Company to Host Conference Call
Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
